Findings from a randomized study, presented at the CHEST conference, the annual meeting of the American College of Chest Physicians, revealed that children with uncontrolled, moderate-to-severe asthma had better lung function over the long term when they received treatment with dupilumab.

In the study, use of add-on dupilumab in children ages 6-11 years appeared to improve forced expiratory volume in 1 second (FEV1) by a pre-bronchodilator average of 0.06 liters at week 2, compared to placebo (P=0.025), and by an average 0.17 liters at week 52 (P<0.0001), noted researchers. There were similar benefits in post-bronchodilator FEV1 (mean difference of 0.09 liters at week 52, compared to placebo; P=0.015).

Investigators, therefore, noted that dupilumab was associated with significant, rapid, and persistent improvements in several aspects of lung function in kids 6 to 11 years of age… (Medpage Today)